KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Retained Earnings (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Retained Earnings for 16 consecutive years, with -$48.1 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings rose 96.43% to -$48.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$48.1 million through Dec 2025, up 96.43% year-over-year, with the annual reading at -$48.1 million for FY2025, 96.43% up from the prior year.
  • Retained Earnings hit -$48.1 million in Q4 2025 for Arbutus Biopharma, up from -$1.4 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$48.1 million in Q4 2025 to a low of -$1.4 billion in Q3 2025.
  • Historically, Retained Earnings has averaged -$527.4 million across 5 years, with a median of -$49.9 million in 2022.
  • Biggest YoY gain for Retained Earnings was 96.43% in 2025; the steepest drop was 2734.55% in 2025.
  • Year by year, Retained Earnings stood at -$48.3 million in 2021, then dropped by 4.45% to -$50.5 million in 2022, then rose by 4.09% to -$48.4 million in 2023, then plummeted by 2680.97% to -$1.3 billion in 2024, then surged by 96.43% to -$48.1 million in 2025.
  • Business Quant data shows Retained Earnings for ABUS at -$48.1 million in Q4 2025, -$1.4 billion in Q3 2025, and -$48.2 million in Q2 2025.